Cromolyn (Standard)

Cromolyn (Standard) is the analytical standard of Cromolyn. This product is intended for research and analytical applications. Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC50 of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects[1][2][3][4][5].

Product Specifications

CAS Number

[16110-51-3]

UNSPSC

12352100

Target

Amyloid-β; GSK-3; NF-κB; Reference Standards

Related Pathways

Neuronal Signaling; NF-κB; Others; PI3K/Akt/mTOR; Stem Cell/Wnt

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease

Smiles

OC(COC1=C2C(C=C(C(O)=O)OC2=CC=C1)=O)COC3=C4C(C=C(C(O)=O)OC4=CC=C3)=O

Molecular Formula

C23H16O11

Molecular Weight

468.37

References & Citations

[1]Oka T, et al. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest. 2012 Oct;92 (10) :1472-82.|[2]Arumugam T, et al. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98 (24) :1806-18.|[3]Granucci EJ, et al. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis. Sci Rep. 2019 Nov 27;9 (1) :17728.|[4]Zhang C, et al. Cromolyn Reduces Levels of the Alzheimer's Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis. Sci Rep. 2018 Jan 18;8 (1) :1144.|[5]Motawi TM, et al. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013 Sep;27 (9) :425-36.